))
STEPHAN JACKMAN - CEO ALZAMEND NEURO : New Lithium-based Drug that Offers Alzheimer's Patients Hope.
Manage episode 378509965 series 3012166
Content provided by Susie Singer Carter and Don Priess, Susie Singer Carter, and Don Priess. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Susie Singer Carter and Don Priess, Susie Singer Carter, and Don Priess or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In Episode 79, my co-host, Don Priess, and I had an enlightening conversation with Stephan Jackman, the CEO of Alzamend Neuro, a clinical stage biotech company committed to “Making Alzheimer’s Just a Memory™.” Stephan shared information about the new lithium-based drug that offers Alzheimer's patients hope.
Stephan is laser focused on his mission to rapidly develop and market safe and effective treatments that address the unmet needs of those living with Alzheimer’s and other neurodegenerative diseases and psychiatric disorders, through advanced research and development.
Their current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer’s is also the sixth leading cause of death in the United States according to a 2021 report from the Alzheimer’s Association, a nonprofit that funds research. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050.
Enjoy the listen.
Love Conquers Alz,
Susie
Alzamend Neuro
Stephan Jackman
JOIN THE MOVEMENT FOR NURSING HOME REFORM BY SUPPORTING THE COMPLETION OF OUR DOCUMENTARY "NO COUNTRY FOR OLD PEOPLE" BY MAKING A TAX DEDUCTIBLE DONATION THROUGH THE NATIONAL CONSUMER VOICE HERE or GO FUND ME
Follow us on Twitter, FB, IG, & TiK Tok 💜
Listen on your favorite platform 💜
If you like what you hear leave us some love. 💜
92 episodes
Share
